Novo Nordisk

Valuation Analysis

About the Company

Novo Nordisk en bref

Novo Nordisk (NVO) is currently trading at 40,82 € with a market capitalization of 180,5 Md €. The trailing P/E ratio stands at 11.21x, with a forward P/E of 14.37x. The 52-week range spans from 30,45 € to 55,63 €; the current price is 26.6% below the yearly high. Year-over-year revenue growth stands at +24.0%. The net profit margin stands at 37.21%.

💰 Dividende

Novo Nordisk pays an annual dividend of 1,56 € per share, representing a yield of 3.82%. The payout ratio stands at 42.59%.

📊 Avis des analystes

12 analystes évaluent Novo Nordisk (NVO) au consensus : Acheter. L'objectif de cours moyen est de 41,56 €, soit un potentiel de +1.81% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 35,02 € à 55,28 €.

Novo Nordisk : la thèse d'investissement en détail

Novo Nordisk (NVO) operates in the Healthcare — specifically Drug Manufacturers - General — and is headquartered in Denmark. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 24% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 67.1% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 83.2%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

Valorisation en contexte

At a PEG of 3.16, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here. The EV/EBITDA multiple of 1.92x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The dividend yield near 3.82% combined with a payout ratio of 42.59% leaves room for further hikes — a track record of consecutive raises is a strong income signal.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Novo Nordisk?

Compare top-rated brokers — low fees, trusted providers, fully regulated.